Document
IPR2024-00107, No. 2019 Exhibit - EX2019 Novo Nordisk Production Letter, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Oct 17, 2023 REDACTED (P.T.A.B. Feb. 2...
Cite Document
IPR2024-00107, No. 2019 Exhibit - EX2019 Novo Nordisk Production Letter, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Oct 17, 2023 REDACTED (P.T.A.B. Feb. 29, 2024)
+ More Snippets
Document
IPR2024-00107, No. 2007 Exhibit - EX2007 Excerpt of Transcript of Dec 13, 2023 Claim Construction Hearing, Novo Nordisk Inc v Mylan Pharmaceuticals Inc, No 23 101 CFC D Del Dec 13, 2023...
Cite Document
IPR2024-00107, No. 2007 Exhibit - EX2007 Excerpt of Transcript of Dec 13, 2023 Claim Construction Hearing, Novo Nordisk Inc v Mylan Pharmaceuticals Inc, No 23 101 CFC D Del Dec 13, 2023 (P.T.A.B. Fe
+ More Snippets
Document
IPR2024-00107, No. 2021 Exhibit - EX2021 Compilation of Rule 30b1 Deposition Notices, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del (P.T.A.B. Feb. 29, 2024)
Cite Document
IPR2024-00107, No. 2021 Exhibit - EX2021 Compilation of Rule 30b1 Deposition Notices, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del (P.T.A.B. Feb. 29, 2024)
+ More Snippets
Document
IPR2024-00107, No. 2011 Exhibit - EX2011 US Patent No 8,114,833 (P.T.A.B. Feb. 29, 2024)
Cite Document
IPR2024-00107, No. 2011 Exhibit - EX2011 US Patent No 8,114,833 (P.T.A.B. Feb. 29, 2024)
+ More Snippets
Document
IPR2024-00107, No. 2006 Exhibit - EX2006 Scheduling Order, Novo Nordisk Inc v Rio Biopharms, Inc, No 122 cv 00294 CFC, Dkt 22 D Del June 30, 2022 (P.T.A.B. Feb. 29, 2024)
Cite Document
IPR2024-00107, No. 2006 Exhibit - EX2006 Scheduling Order, Novo Nordisk Inc v Rio Biopharms, Inc, No 122 cv 00294 CFC, Dkt 22 D Del June 30, 2022 (P.T.A.B. Feb. 29, 2024)
+ More Snippets
Document
IPR2024-00107, No. 3001 Exhibit - Exhibit 3001 (P.T.A.B. May. 28, 2024)
Cite Document
IPR2024-00107, No. 3001 Exhibit - Exhibit 3001 (P.T.A.B. May. 28, 2024)
+ More Snippets
Document
IPR2024-00107, No. 2031 Exhibit - EX2031 Email Exchange Between Counsel for Petitioner and Counsel for Patent Owner Regarding Request To File Stipulation (P.T.A.B. May. 20, 2024)
Cite Document
IPR2024-00107, No. 2031 Exhibit - EX2031 Email Exchange Between Counsel for Petitioner and Counsel for Patent Owner Regarding Request To File Stipulation (P.T.A.B. May. 20, 2024)
+ More Snippets
Document
IPR2024-00107, No. 1060 Exhibit - WO 2011058193 (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1060 Exhibit - WO 2011058193 (P.T.A.B. Nov. 2, 2023)
+ More Snippets
Document
IPR2024-00107, No. 1048 Exhibit - FDA Guidance for Industry, Exposure Response Relationships Study Design, (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1048 Exhibit - FDA Guidance for Industry, Exposure Response Relationships Study Design, (P.T.A.B. Nov. 2, 2023)
+ More Snippets
Document
IPR2023-00724, No. 2557 Exhibit - EX2557 Transcript of July 9, 2024 Deposition of Arthur Z Schwartzbard, MD (P.T.A.B. Aug. 5, 2024)
Cite Document
IPR2023-00724, No. 2557 Exhibit - EX2557 Transcript of July 9, 2024 Deposition of Arthur Z Schwartzbard, MD (P.T.A.B. Aug. 5, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2602 Exhibit - EX2602 J Newman, A Schwartzbard, et al, The Changing Landscape of Dia betes Therapy for Cardiovascular Risk Reduction, JACC State of the Art Review, J...
Cite Document
IPR2023-00724, No. 2602 Exhibit - EX2602 J Newman, A Schwartzbard, et al, The Changing Landscape of Dia betes Therapy for Cardiovascular Risk Reduction, JACC State of the Art Review, JACC Vol 72 201
+ More Snippets
Document
IPR2023-00724, No. 2601 Exhibit - EX2601 T Wilcox, A Schwartzbard, et al, Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists, JACC Focus Seminar, JACC Vol...
Cite Document
IPR2023-00724, No. 2601 Exhibit - EX2601 T Wilcox, A Schwartzbard, et al, Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists, JACC Focus Seminar, JACC Vol 75 2020 Marked
+ More Snippets
Document
IPR2023-00724, No. 2544 Exhibit - EX2544 Defendants’ Notice of Deposition of Stephanie Dechiaro, In re Ozempic Semaglutide Patent Litigation, No 122 cv 03038 CFC Dkt 265 (P.T.A.B. Jul. 3...
Cite Document
IPR2023-00724, No. 2544 Exhibit - EX2544 Defendants’ Notice of Deposition of Stephanie Dechiaro, In re Ozempic Semaglutide Patent Litigation, No 122 cv 03038 CFC Dkt 265 (P.T.A.B. Jul. 31, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2542 Exhibit - EX2542 Sun Pharmaceutical Industries Ltd’s and Sun Pharmaceutical In dustries Inc’s Stipulation of Invalidity Contentions, In re Ozempic Semaglutide Pate...
Cite Document
IPR2023-00724, No. 2542 Exhibit - EX2542 Sun Pharmaceutical Industries Ltd’s and Sun Pharmaceutical In dustries Inc’s Stipulation of Invalidity Contentions, In re Ozempic Semaglutide Patent Litigati
+ More Snippets
Document
IPR2023-00724, No. 1055 Exhibit - Landersdorfer 2011b (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1055 Exhibit - Landersdorfer 2011b (P.T.A.B. Mar. 16, 2023)
+ More Snippets